Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added ...
MONROE TOWNSHIP, NJ, & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, ...
− Oral presentation highlighted at 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting – MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a ...
A PSA of 127 indicated a high probability of prostate cancer, leading to immediate Lupron ADT therapy and radiation treatment ...
But despite this good news, the overall number of new prostate cancer cases and deaths is on the rise in the U.S.: 2014: 182,806 new prostate cancer cases 2019: 224,733 new prostate cancer cases ...
While prognoses for prostate cancer patients were once measured in months, experts say that advances in treatment and diagnosis now improve survival by years. By Gina Kolata Prostate cancer experts ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback